Stro-002-Gm1 A Phase 1 Open-Label, Safety, Pharmacokinetic And Preliminary Efficacy Study Of Stro-002, An Anti-Folate Receptor Alpha (Folra) Antibody-Drug Conjugate (Adc), In Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube Or Pr
Posted Date: Jul 6, 2021
- Investigator: Amanda Jackson
- Specialties: Cancer, Oncology
- Type of Study: Drug
The primary objective of this study is to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks. Efficacy will be measured by the Incidence of Treatment-Emergent Adverse Events and evaluating preliminary anti-tumor activity. Patients in the experimental arm will receive STRO-002 treatment at increasing dose levels through IV antibody drug conjugate.
Participants Must Have Evidence Of Measureable Disease As Defined By Recist 1.1, Must Have Ecog Performance Status Of 0-1, Must Have Qtcf <500 Msec. No Low Grade Ovarian Carcinoma. No Clear Cell, Mucinous And Sarcomatous Ovarian Carcinomas. No Prior Treatment With A Folra-Targeting Adcs Or Folra-Targeting Vaccines. No Subjects Who Are Platinum-Refractory During Frontline Treatment. No Prior Anticancer Therapy. No Clinically Significant Pre-Exisiting Ocular Disorders. No Sensory Or Motor Neuropathy = Grade 2.
Phase 1, Ovarian, Endometrial
For More Information:
Uc Cancer Center